In conclusion, we achieved 5.7% of objective response and 40% of stabilisation including 11.4% prolonged stabilisation >8 months with IL-2, IFNα, 5-FU in patients with renal cell carcinoma in whom previous first-line immunotherapy failed. The gene discussed is IFNA2; the disease is hereditary clear cell renal cell carcinoma.